247 publications
Ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma
Zorginstituut Nederland has completed its assessment whether ipilimumab/nivolumab (Yervoy®/Opdivo®) for the first-line treatment ...
Explanation of the Interest Form - CBG-ZIN Parallel Procedures pilot
Accelerating patient access to reimbursable innovative medicines has been on the wish list of the government, patient ...
Venetoclax (Venclyxto®) in combination with rituximab for the treatment of chronic lymphocytic leukaemia (CLL)
Zorginstituut Nederland has completed its assessment whether venetoclax (Venclyxto®) in combination with rituximab for the ...
Tezacaftor/ivacaftor (Symkevi®) with ivacaftor monopreparation (Kalydeco®) for the treatment of cystic fibrosis
Zorginstituut Nederland carried out an assessment in relation to extending the specific conditions for the medicinal product ...
Brexpiprazole (Rxulti®) for the treatment of schizophrenia in adults
Zorginstituut Nederland carried out a marginal assessment whether the product brexpiprazole (Rxulti®) can be accepted into the ...
Pitolisant (Wakix®) for the treatment of narcolepsy in adults
Zorginstituut Nederland carried out a marginal assessment whether pitolisant (Wakix®) is interchangeable with a drug currently ...
Glycopyrronium bromide (Sialanar®) for the symptomatic treatment of severe sialorrhoea
Zorginstituut Nederland carried out an assessment whether the product glycopyrronium bromide (Sialanar®) is interchangeable with ...
Tolvaptan (Jinarc ®) for the treatment of chronic kidney disease - alteration of the specific conditions
Zorginstituut Nederland carried out an assessment whether the specific conditions for tolvaptan (Jinarc ®) can be altered. ...
Durvalumab (Imfinzi®) for the treatment of locally advanced, unresectable, non-small cell lung cancer
Zorginstituut Nederland has completed its assessment of durvalumab (Imfinzi®) as monotherapy for the treatment of locally ...